Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Conditions: B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma Interventions: Biological: Zilovertamab vedotin Sponsors: Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Bone Cancers | Brain | Burkitt Lymphoma | Cancer & Oncology | Ewing's Sarcoma | Hematology | Leukemia | Lymphoma | Merck | Neuroblastoma | Neurology | Pediatrics | Research | Sarcomas